AU740475B2 - The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances - Google Patents
The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances Download PDFInfo
- Publication number
- AU740475B2 AU740475B2 AU76546/98A AU7654698A AU740475B2 AU 740475 B2 AU740475 B2 AU 740475B2 AU 76546/98 A AU76546/98 A AU 76546/98A AU 7654698 A AU7654698 A AU 7654698A AU 740475 B2 AU740475 B2 AU 740475B2
- Authority
- AU
- Australia
- Prior art keywords
- formula
- compound
- group
- alkyl
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 238000011282 treatment Methods 0.000 title claims abstract description 9
- 239000003814 drug Substances 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 18
- 206010008118 cerebral infarction Diseases 0.000 claims abstract description 8
- 208000006011 Stroke Diseases 0.000 claims abstract description 5
- 208000030886 Traumatic Brain injury Diseases 0.000 claims abstract description 5
- 150000001875 compounds Chemical class 0.000 claims description 36
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 21
- -1 nitro, amino Chemical group 0.000 claims description 17
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 12
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 10
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 7
- 125000005843 halogen group Chemical group 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 7
- 150000003852 triazoles Chemical group 0.000 claims description 7
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 6
- 150000002367 halogens Chemical class 0.000 claims description 6
- 125000005842 heteroatom Chemical group 0.000 claims description 6
- 241000124008 Mammalia Species 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 229910052717 sulfur Inorganic materials 0.000 claims description 4
- 125000006569 (C5-C6) heterocyclic group Chemical group 0.000 claims description 3
- 125000003342 alkenyl group Chemical group 0.000 claims description 3
- 125000000304 alkynyl group Chemical group 0.000 claims description 3
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims description 3
- 125000002393 azetidinyl group Chemical group 0.000 claims description 3
- 229910052757 nitrogen Inorganic materials 0.000 claims description 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 3
- 125000001424 substituent group Chemical group 0.000 claims description 3
- 125000004429 atom Chemical group 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 5
- 206010061216 Infarction Diseases 0.000 claims 1
- 230000007574 infarction Effects 0.000 claims 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 16
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 8
- 229960005305 adenosine Drugs 0.000 description 8
- 101150051188 Adora2a gene Proteins 0.000 description 7
- 125000003545 alkoxy group Chemical group 0.000 description 7
- 108020003175 receptors Proteins 0.000 description 7
- 102000005962 receptors Human genes 0.000 description 7
- 125000004438 haloalkoxy group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 108050000203 Adenosine receptors Proteins 0.000 description 2
- 102000009346 Adenosine receptors Human genes 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- MSJODEOZODDVGW-UHFFFAOYSA-N 9-chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine Chemical compound N=1N2C(N)=NC3=CC=C(Cl)C=C3C2=NC=1C1=CC=CO1 MSJODEOZODDVGW-UHFFFAOYSA-N 0.000 description 1
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
- 102000007471 Adenosine A2A receptor Human genes 0.000 description 1
- 108010085277 Adenosine A2A receptor Proteins 0.000 description 1
- 101150078577 Adora2b gene Proteins 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010080192 Purinergic Receptors Proteins 0.000 description 1
- 102000000033 Purinergic Receptors Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000003556 anti-epileptic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 230000000949 anxiolytic effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007885 bronchoconstriction Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001627 cerebral artery Anatomy 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000010231 histologic analysis Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 229940124549 vasodilator Drugs 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI001190A IT1291372B1 (it) | 1997-05-21 | 1997-05-21 | Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie |
| ITMI97A001190 | 1997-05-21 | ||
| PCT/EP1998/002852 WO1998052568A1 (en) | 1997-05-21 | 1998-05-14 | THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU7654698A AU7654698A (en) | 1998-12-11 |
| AU740475B2 true AU740475B2 (en) | 2001-11-08 |
Family
ID=11377184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU76546/98A Ceased AU740475B2 (en) | 1997-05-21 | 1998-05-14 | The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances |
Country Status (9)
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR028621A1 (es) * | 2000-05-26 | 2003-05-14 | Schering Corp | Antagonistas receptores de adenosina a2a |
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| EP1575916B1 (en) | 2001-08-31 | 2013-05-22 | The Rockefeller University | Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain |
| CA2430328A1 (en) * | 2001-09-28 | 2003-04-10 | Kyowa Hakko Kogyo Co., Ltd. | Receptor antagonist |
| US6653315B2 (en) | 2001-10-15 | 2003-11-25 | Schering Corporation | Adenosine A2a receptor antagonists |
| EP1448565B1 (en) | 2001-11-30 | 2009-12-30 | Schering Corporation | ADENOSINE A2a RECEPTOR ANTAGONISTS |
| EP1453836B1 (en) | 2001-11-30 | 2007-03-28 | Schering Corporation | BICYCLIC [1,2,4] -TRIAZOLE ADENOSINE A2a RECEPTOR ANTAGONISTS |
| TW200300686A (en) | 2001-11-30 | 2003-06-16 | Schering Corp | Adenosine A2a receptor antagonists |
| JP4527712B2 (ja) | 2003-04-23 | 2010-08-18 | シェーリング コーポレイション | ２−アルキニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニストおよび２−アルケニル−ピラゾロ−［４，３−ｅ］−１，２，４−トリアゾロ−［１，５−ｃ］−ピリミジンアデノシンＡ２ａレセプターアンタゴニスト |
| EP1745047B1 (en) | 2004-04-21 | 2010-03-24 | Schering Corporation | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists |
| EP1888534B1 (en) | 2005-06-06 | 2017-07-26 | Intra-Cellular Therapies, Inc. | Organic compounds |
| EP1934227B1 (en) | 2005-09-19 | 2011-12-21 | Schering Corporation | 2-HETEROARYL-PYRAZOLO-[4, 3-e]-1, 2, 4-TRIAZOLO-[1,5-c]-PYRIMIDINE AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| AR056080A1 (es) | 2005-09-23 | 2007-09-19 | Schering Corp | 7-[2-[4-(6-fluoro-3-metil-1,2-benciosoxazol-5-il)-1-piperazinil]etil]-2-(1-propinil)-7h-pirazol-[4,3-e]-[1,2,4]-triazol-[1,5-c] -pirimidin-5-amine |
| ES2273599B1 (es) | 2005-10-14 | 2008-06-01 | Universidad De Barcelona | Compuestos para el tratamiento de la fibrilacion auricular. |
| EP2023729B1 (en) | 2006-06-06 | 2016-05-04 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9198924B2 (en) | 2006-11-13 | 2015-12-01 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP5837278B2 (ja) | 2006-12-05 | 2015-12-24 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| US7691869B2 (en) | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
| CN104370918A (zh) | 2007-12-06 | 2015-02-25 | 武田药品工业株式会社 | 有机化合物 |
| CN101969774A (zh) | 2007-12-06 | 2011-02-09 | 细胞内治疗公司 | 有机化合物 |
| US8222259B2 (en) | 2008-03-04 | 2012-07-17 | Schering Corporation | 1,2,4-triazolo[4,3-c]pyrimidin-3-one and pyrazolo[4,3-e]-1,2,4-triazolo[4,3-c]pyrimidin-3-one compounds for use as adenosine A2a receptor antagonists |
| WO2010009190A1 (en) * | 2008-07-16 | 2010-01-21 | King Pharmaceuticals Research And Development, Inc. | Methods of treating atherosclerosis |
| BRPI0922348A2 (pt) | 2008-12-06 | 2015-08-11 | Intracellular Therapies Inc | Compostos orgânicos |
| MA32940B1 (fr) | 2008-12-06 | 2012-01-02 | Intra Cellular Therapies Inc | Composes organiques |
| AU2009322899A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| AU2009322904A1 (en) | 2008-12-06 | 2010-06-10 | Intra-Cellular Therapies, Inc. | Organic compounds |
| BRPI0922808A2 (pt) | 2008-12-06 | 2018-05-29 | Intracellular Therapies Inc | compostos orgânicos |
| EP2358204B1 (en) | 2008-12-06 | 2015-08-05 | Intra-Cellular Therapies, Inc. | 4,5,7,8-tetrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine compounds as PDE1 inhibitors. |
| WO2010098839A1 (en) | 2009-02-25 | 2010-09-02 | Intra-Cellular Therapies, Inc. | Pde 1 inhibitors for ophthalmic disorders |
| JP2012526810A (ja) | 2009-05-13 | 2012-11-01 | イントラ−セルラー・セラピーズ・インコーポレイテッド | 有機化合物 |
| JP6166534B2 (ja) | 2009-08-05 | 2017-07-19 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規調節タンパク質および阻害剤 |
| US9434730B2 (en) | 2010-05-31 | 2016-09-06 | Intra-Cellular Therapies, Inc. | PDE1 inhibitor compounds |
| WO2011153138A1 (en) | 2010-05-31 | 2011-12-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| TW201206937A (en) | 2010-05-31 | 2012-02-16 | Intra Cellular Therapies Inc | Organic compounds |
| EP2590657A4 (en) | 2010-05-31 | 2014-02-12 | Intra Cellular Therapies Inc | ORGANIC CONNECTIONS |
| US10561656B2 (en) | 2011-06-10 | 2020-02-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| WO2014101120A1 (en) | 2012-12-28 | 2014-07-03 | Merck Sharp & Dohme Corp. | Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties |
| WO2014127331A1 (en) | 2013-02-17 | 2014-08-21 | Intra-Cellular Therapies, Inc. | Novel uses |
| JP2016518343A (ja) | 2013-03-15 | 2016-06-23 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規使用 |
| US9073936B2 (en) | 2013-03-15 | 2015-07-07 | Intra-Cellular Therapies, Inc. | Organic compounds |
| JP6696904B2 (ja) | 2014-01-08 | 2020-05-20 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 製剤および医薬組成物 |
| ES2732442T3 (es) | 2014-06-20 | 2019-11-22 | Intra Cellular Therapies Inc | Compuestos orgánicos |
| WO2016022893A1 (en) | 2014-08-07 | 2016-02-11 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US9546175B2 (en) | 2014-08-07 | 2017-01-17 | Intra-Cellular Therapies, Inc. | Organic compounds |
| US10285992B2 (en) | 2014-08-07 | 2019-05-14 | Intra-Cellular Therapies, Inc. | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods |
| BR112017005533B1 (pt) | 2014-09-17 | 2023-10-10 | Intra-Cellular Therapies, Inc | Compostos inibidores de fosfodiesterase 1 (pde1), composição farmacêutica que compreende os ditos compostos e usos dos mesmos no tratamento de uma doença, distúrbio, e/ou lesão do snc e no tratamento e/ou na profilaxia de uma doença, distúrbio e/ou lesão do snp |
| US10472347B2 (en) | 2014-11-18 | 2019-11-12 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with A2A antagonist properties |
| BR112017012007B1 (pt) | 2014-12-06 | 2022-11-01 | Intra-Cellular Therapies, Inc | Compostos orgânicos inibitórios de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2 |
| KR102562576B1 (ko) | 2014-12-06 | 2023-08-01 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US10138212B2 (en) | 2015-02-06 | 2018-11-27 | Merck Sharp & Dohme Corp. | Aminoquinazoline compounds as A2A antagonist |
| WO2016200717A1 (en) | 2015-06-11 | 2016-12-15 | Merck Sharp & Dohme Corp. | Aminopyrazine compounds with a2a antagonist properties |
| WO2017008205A1 (en) | 2015-07-10 | 2017-01-19 | Merck Sharp & Dohme Corp. | Substituted aminoquinazoline compounds as a2a antagonist |
| JP2019510039A (ja) | 2016-03-28 | 2019-04-11 | イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． | 新規組成物および方法 |
| JP7134168B6 (ja) | 2016-09-12 | 2024-02-02 | イントラ－セルラー・セラピーズ・インコーポレイテッド | 新規使用 |
| EP3723754A4 (en) | 2017-12-13 | 2021-05-19 | Merck Sharp & Dohme Corp. | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES |
| WO2019152697A1 (en) | 2018-01-31 | 2019-08-08 | Intra-Cellular Therapies, Inc. | Novel uses |
| EP4025202A4 (en) | 2019-09-03 | 2023-08-02 | Intra-Cellular Therapies, Inc. | NOVEL CONNECTIONS |
| CN111072676B (zh) * | 2019-12-12 | 2021-07-16 | 广东东阳光药业有限公司 | 含氮稠合三环衍生物及其用途 |
| US12364695B2 (en) | 2020-06-02 | 2025-07-22 | Intra-Cellular Therapies, Inc. | Methods of treating inflammatory disease |
-
1997
- 1997-05-21 IT IT97MI001190A patent/IT1291372B1/it active IP Right Grant
-
1998
- 1998-05-14 AT AT98924313T patent/ATE209492T1/de active
- 1998-05-14 JP JP54991798A patent/JP2002502370A/ja active Pending
- 1998-05-14 CN CN98805120A patent/CN1255854A/zh active Pending
- 1998-05-14 CA CA002289847A patent/CA2289847A1/en not_active Abandoned
- 1998-05-14 EP EP98924313A patent/EP0983068B1/en not_active Expired - Lifetime
- 1998-05-14 WO PCT/EP1998/002852 patent/WO1998052568A1/en active IP Right Grant
- 1998-05-14 AU AU76546/98A patent/AU740475B2/en not_active Ceased
- 1998-05-14 DE DE69802679T patent/DE69802679D1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| DE69802679D1 (de) | 2002-01-10 |
| EP0983068A1 (en) | 2000-03-08 |
| ATE209492T1 (de) | 2001-12-15 |
| EP0983068B1 (en) | 2001-11-28 |
| WO1998052568A1 (en) | 1998-11-26 |
| ITMI971190A1 (it) | 1998-11-21 |
| ITMI971190A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) | 1997-05-21 |
| AU7654698A (en) | 1998-12-11 |
| CA2289847A1 (en) | 1998-11-26 |
| IT1291372B1 (it) | 1999-01-07 |
| CN1255854A (zh) | 2000-06-07 |
| JP2002502370A (ja) | 2002-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU740475B2 (en) | The use of 1,2,4-triazolo(1,5-c)pyrimidine heterocyclic analogues for the preparation of medicaments useful for the treatment of cerebrovascular disturbances | |
| EP0856003B1 (en) | 1,2,4-TRIAZOLO 1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES HAVING ANTAGONISTIC ACTIVITY ON ADENOSINE A 2a? RECEPTOR | |
| JP6038250B2 (ja) | 有機化合物 | |
| EP2081431B1 (en) | Organic compounds | |
| JP4248239B2 (ja) | プリン作用性レセプターアンタゴニストとしてのピロロ［２，３−ｄ］ピリミジンおよびそれらの使用 | |
| US20100323997A1 (en) | Novel uses | |
| JP7134168B2 (ja) | 新規使用 | |
| TW200914048A (en) | Combinations for the treatment of B-cell proliferative disorders | |
| EP2708540B1 (en) | Pyrimido-diazepinone compound | |
| PL217269B1 (pl) | Pochodne triazoliloimidazopirydyny i triazolilopuryny, zawierająca je kompozycja farmaceutyczna, ich zastosowanie, sposób ich otrzymywania oraz związki pośrednie wykorzystywane w tym sposobie | |
| EP2258372A1 (en) | A2A antagonists for use in the treatment of motor disorders | |
| CN113056272A (zh) | 新的喹唑啉egfr抑制剂 | |
| JP2021506868A (ja) | Ｐｄｅ１阻害剤としての大環状分子 | |
| Baraldi et al. | Pyrazolo-triazolo-pyrimidine derivatives as adenosine receptor antagonists: a possible template for adenosine receptor subtypes? | |
| WO2010053127A1 (ja) | α1GABAA受容体またはα5GABAA受容体の調整剤 | |
| KR20070008689A (ko) | 아데노신 ａ１ 수용체 길항제 및 알도스테론 억제제를포함하는 병용 요법 | |
| MXPA99010735A (en) | THE USE OF 1,2,4-TRIAZOLO[1,5-c]PYRIMIDINE HETEROCYCLIC ANALOGUES FOR THE PREPARATION OF MEDICAMENTS USEFUL FOR THE TREATMENT OF CEREBROVASCULAR DISTURBANCES | |
| KR20130087058A (ko) | 피리미딜아미노벤즈아미드와 ｍｔｏｒ 키나제 억제제의 조합물 | |
| JP2641556B2 (ja) | ５―（置換アミノ）―８―（フエニルまたは置換フエニル）―３Ｈ，６Ｈ―１，４，５ａ，８ａ―テトラアザアセナフチレン―３―オン | |
| WO2007135387A1 (en) | Inhibitor of adenylyl cyclase for treating a disorder of the circadian rhythm | |
| HK40054977A (en) | Novel quinazoline egfr inhibitors | |
| WO2024092047A1 (en) | Administration of pyrrolopyrimidine-based kinase inhibitors for treatment of psoriasis | |
| CZ204899A3 (cs) | 3-Pyridylové enantiomery a jejich použití jako analgetik |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |